Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 13, 2020
Daily News
November 13, 2020
- Some Hospitals Shun New Nichi-Iko Generics after Massive Recalls, President Reveals
November 13, 2020
- Generic Makers Seeking to Invalidate Feburic Patent, Can They Get Full Indications?
November 13, 2020
- Fuji Pharma, M3 Join Hands on Dysmenorrhea Med in Japan
November 13, 2020
- Voluntary Recalls Launched for Pfizer/MSD’s Antidepressant Trazodone
November 13, 2020
- HPV Vaccine Is “Social Justice”: LDP Lawmaker
November 13, 2020
- Sagent Launches US PII to Test Camostat Mesilate for COVID-19
November 13, 2020
- Humira’s Pediatric Dosage Filed for Ulcerative Colitis in Japan: AbbVie
November 13, 2020
- Osaka Univ. Spin-Off Boots Up to Develop First Treatment for Skeletal Muscle Damage, Atrophy
November 13, 2020
- PeptiDream, 4 Other Firms Establish JV to Develop COVID-19 Therapeutics
November 13, 2020
- Ex-Daiichi Sankyo Chairman Kiyoshi Morita Dies at 81
November 13, 2020
- Fujifilm Grants Rights to Patent on iPS Cell Generation to Lonza
November 13, 2020
- Taiho Obtains Japan Rights for US Firm’s Loculated Pleural Effusion Med
November 13, 2020
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…